Sound Ear Check (SEC) in Hearing Diagnostics in Young Children
Launched by VESA LAHDES · Sep 7, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The Sound Ear Check (SEC) trial is studying a new hearing test for young children aged 3 to 10 who are otherwise healthy and have been referred for a surgical procedure called tympanostomy, which involves placing small tubes in the ears to help with fluid drainage. The goal of the trial is to see how well the SEC test works both before the surgery, when the middle ear has fluid, and one month after the surgery, when the ear is expected to be dry. Researchers will also gather information about the children’s ear health by using a questionnaire called the Otitis Media 6 before and after the procedure.
To participate in this study, children and their parents must speak Finnish. However, children who have had prior ear surgery (other than the tympanostomy), have any developmental disorders, or have experienced hearing loss that is not caused by ear infections will not be eligible. If your child qualifies and decides to join, they will undergo the SEC hearing test and answer questions about their ear health, helping researchers understand the effectiveness of this new test for diagnosing hearing issues in young children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Finnish speaking (child and parent)
- Exclusion Criteria:
- • Prior sensorineural hearing loss
- • developmental disorder
- • Prior ear surgery (except tympanostomy insertion)
About Vesa Lahdes
Vesa Lahdes is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based practices, Vesa Lahdes collaborates with healthcare professionals and research institutions to design and conduct rigorous clinical trials. The organization prioritizes ethical standards and regulatory compliance, ensuring the safety and well-being of participants while aiming to deliver meaningful advancements in healthcare. Through a passion for scientific excellence and patient-centered approaches, Vesa Lahdes seeks to contribute significantly to the fields of medicine and pharmacology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Turku, , Finland
Patients applied
Trial Officials
Lotta Haavisto, PhD
Principal Investigator
Hospital District of Southwest Finland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials